The Effect of Incubation Time on the Activity and Stability of Factor VIII during the Preparation Process

2019 ◽  
Author(s):  
Kourosh Kabir ◽  
Hassan Hosseini ◽  
Mehdy Jahed Zargar ◽  
Zeynab Mandeh ◽  
Fatemeh Amrollahi ◽  
...  
Keyword(s):  
Factor Viii ◽  
Human Plasma ◽  
Blood Group ◽  
Recombinant Dna ◽  
Autoimmune Disorder ◽  
Fresh Frozen Plasma ◽  
Clotting Factor ◽  
Recombinant Dna Technology ◽  
Fviii Activity ◽  
Fresh Frozen

Background and Aims: Hemophilia is a rare autoimmune disorder caused by autoantibodies directed in the majority of the cases against clotting factor VIII (FVIII). FVIII is extracted from human plasma or engineered from mammalian cell cultures using recombinant DNA technology. In Iran, most of the used FVIII is prepared from human plasma in Iranian Blood Transfusion Organization. It was seen important to estimate its stability and activity from bleeding time until product preparation.Material and Methods: In the analytical study, 60 healthy male donors (20-50 years old), 15 donors from each blood group, were selected after obtaining informed consent. Donors' blood was collected in QUADRI-PACKs and centrifuged after keeping at 24°C for 2 hours. The separated plasma was divided into three groups and incubated in the lab (22°C) for 0, 90, and 180 minutes, respectively. Then, samples were stored at -20°C for one month. Afterward, the plasma was thawed, and FVIII activity was assayed.Results: The activity of FVIII significantly (p<0.05) reduced by delay in freezing; after the time of 0 min: 134.84%±42, after 90 min: 126.88%±38, after 180 min: 120.22%±34. At all incubation times, the highest and the lowest FVIII activity were observed in A and O blood groups, respectively (p<0.05). FVIII activity was increased along with increasing age up to 35-40, but it decreased in subjects of 40-50 years old. These experiments confirmed that the longer the delay in freezing fresh frozen plasma, the greater the decrease in FVIII stability.Conclusions:. According to the results of this study, the best blood donors for FVIII product are those with blood group A in the age range of 40-35 years.

scholarly journals VOLUME PLASMA DAN FAKTOR VIII DALAM KRIOPRESIPITAT

2016 ◽  
Vol 19 (1) ◽  
pp. 9
Author(s):  
Dian Widyaningrum ◽  
Purwanto AP ◽  
Julia Setyati
Keyword(s):  
Factor Viii ◽  
Blood Group ◽  
Von Willebrand Factor ◽  
Plasma Volume ◽  
Fresh Frozen Plasma ◽  
Factor Viii Level ◽  
Viii Level ◽  
Fresh Frozen ◽  
Von Willebrand ◽  
Willebrand Factor

Blood product such as cryoprecipitate required a quality control. This includes development, implementation and the standard operating procedures use of each step of the process in the production of cryoprecipitated substance to ensure that the produced product contains a minimum of 80 international units (IU) of factor VIII. Cryoprecipitation is prepared from fresh frozen plasma that thawed and centrifuge by immediate spinning the excess plasma which then removed and leaving approximately 40ml which deposit 10 mL cryoprecipitate. One unit of cryoprecipitate contain 70–80 IU/unit factor VIII, ≥100 mg/unit von Willebrand factor, fibrinogen 5–10 mg/dL. The levels of factor VIII and von Willebrand factor (VWF) lowered in individuals with blood group O compared to individuals groups with non-O blood. This research is aimed to investigate whether plasma volume are correlated with the levels of factor VIII in cryoprecipitation. In this study purposive sampling is done in which 25 bags of cryoprecipitate materials (was storage for 11 months) from all types of blood group which were taken from storage, thawed, weighed and the plasma volume measured. Factor VIII was measured by coagulometric method. The researcher used Spearman correlation test to analyze the product, with significance degree p<0.05 and confidence interval 95%. In this study it is found plasma volume which was not related to the factor VIII level in cryoprecipitattion substance (p=0.585). Mean plasma volume of the cryoprecipitated matter was 56 mL, mean factor VIII was 83.3UI. Highest factor VIII level was 160.6 UI of cryoprecipitated blood group AB and lowest factor VIII level was 21.3 UI of cryoprecipitated blood group A.

scholarly journals INFLUENCE OF ABO BLOOD GROUP ON FACTOR VIII AND FACTOR V LEVELS IN FRESH FROZEN PLASMA

2020 ◽  
Vol 42 ◽  
pp. 404-405
Author(s):  
C.M. Wink ◽  
J.S. Palaoro ◽  
D. Glimm ◽  
A.A.C. Araujo ◽  
C.S.R. Araujo
Keyword(s):  
Factor Viii ◽  
Blood Group ◽  
Fresh Frozen Plasma ◽  
Abo Blood Group ◽  
Factor V ◽  
Fresh Frozen ◽  
Frozen Plasma

scholarly journals Thermolability of factor VIII in donor fresh frozen blood plasma

2021 ◽  
Vol 66 (4) ◽  
pp. 593-609
Author(s):  
V. N. Lemondzhava ◽  
A. V. Chechetkin ◽  
A. G. Gudkov ◽  
V. Yu. Leushin ◽  
A. D. Kasianov ◽  
...  
Keyword(s):  
Factor Viii ◽  
Blood Plasma ◽  
Clotting Factor ◽  
Donor Blood ◽  
Fviii Activity ◽  
New Knowledge ◽  
Fresh Frozen ◽  
Technological Barriers ◽  
The Moment

A criterion of the quality of fresh frozen blood plasma (FFP) is the activity of clotting factor VIII (FVIII).Aim — to identify technological barriers in the study of FVIII thermolability and to describe the requirements for experiments, providing new knowledge about the thermolability of this factor.Basic information. An analysis of domestic and foreign publications devoted to the study of the mechanisms responsible for reducing the value of FVIII activity in donor blood plasma from the moment of donation to the moment of transfusion was carried out. Data on the decrease in FVIII activity at various stages of work with blood plasma are presented. An analysis of methods for preparing samples for studying changes in the values of FVIII in donor blood plasma was performed. The existence of contradictory conclusions about the infl uence on the change in FVIII at the thawing stage of various values of the effects on FFP and poor knowledge of the change in the indicator at the stage of heating to the transfusion temperature after the end of the phase transition in the samples was established. The fundamental differences in the methods of preparing and conducting experiments in previous works are determined. Methods for increasing the reliability of experimental results for studying the thermal lability of FVIII are proposed.

The Recovery of Factor VIII from Fresh-Frozen, Indated and Outdated Human Plasma

1976 ◽  
Vol 36 (01) ◽  
pp. 071-077 ◽  
Author(s):  
Daniel E. Whitman ◽  
Mary Ellen Switzer ◽  
Patrick A. McKee
Keyword(s):  
Factor Viii ◽  
Polyacrylamide Gel Electrophoresis ◽  
Sodium Dodecyl ◽  
The United States ◽  
Fresh Frozen Plasma ◽  
Red Cross ◽  
Random Samples ◽  
Fresh Frozen ◽  
Factor Viii Concentrates ◽  
Frozen Plasma

SummaryThe availability of factor VIII concentrates is frequently a limitation in the management of classical hemophilia. Such concentrates are prepared from fresh or fresh-frozen plasma. A significant volume of plasma in the United States becomes “indated”, i. e., in contact with red blood cells for 24 hours at 4°, and is therefore not used to prepare factor VIII concentrates. To evaluate this possible resource, partially purified factor VIII was prepared from random samples of fresh-frozen, indated and outdated plasma. The yield of factor VIII protein and procoagulant activity from indated plasma was about the same as that from fresh-frozen plasma. The yield from outdated plasma was substantially less. After further purification, factor VIII from the three sources gave a single subunit band when reduced and analyzed by sodium dodecyl sulfate polyacrylamide gel electrophoresis. These results indicate that the approximately 287,000 liters of indated plasma processed annually by the American National Red Cross (ANRC) could be used to prepare factor VIII concentrates of good quality. This resource alone could quadruple the supply of factor VIII available for therapy.

scholarly journals Case Report on Management of Combined Factor V and factor VIII Deficiency during Pregnancy

2021 ◽  
pp. 1-2
Author(s):  
Dr. Kirti Solanki ◽  
Dr. Swati Kochar ◽  
Dr. Shweta Choudhary ◽  
Dr. Priyanka Gaur ◽  
Dr. Krishna Krishna
Keyword(s):  
Factor Viii ◽  
Post Partum ◽  
Autosomal Recessive Disorder ◽  
Fresh Frozen Plasma ◽  
Factor V ◽  
Bleeding Tendency ◽  
Factor Viii Deficiency ◽  
Risk Of Bleeding ◽  
Increased Risk ◽  
Fresh Frozen

Combined factor V and factor VIII deficiency (CF5F8D) is a rare autosomal recessive disorder associated with mild to moderate risk of bleeding tendency. These patients have an increased risk of bleeding after surgical procedures. Pregnant women are at increased risk of having a miscarriage, placental abruption, or post partum hemorrhage. Management of these patients requires the replacement of deficient factors. We are reporting a case of management of a 31-year old second gravida female with combined factor V and factor VIII deficiency, who was transfused with fresh frozen plasma before and during labor to prevent bleeding episodes.

Leukemia and Hemophilia

PEDIATRICS ◽  
1986 ◽  
Vol 78 (3) ◽  
pp. 544-544
Author(s):  
SINASI OZSOYLU
Keyword(s):  
Factor Viii ◽  
Hemophilia A ◽  
Fresh Frozen Plasma ◽  
Fresh Frozen ◽  
Viii And Ix ◽  
Immune Changes ◽  
Frozen Plasma

To the Editor.— I enjoyed reading the paper by Aronis et al,1 and would like to bring to your attention that we have also recently observed leukemia in two patients with hemophilia A and B, 10 and 1½ years of age, respectively.2 Because commercial factor VIII and IX were not used and only blood, fresh frozen plasma, and plasma were given on a few occasions, it was less likely that AIDS-like immune changes were responsible for the leukemia in our patients.

scholarly journals 52 year Male with Haemophila-A; Presented with Scrotal Haematoma: Managed in Resource Constraint Settings - A Case Report

2019 ◽  
Vol 10 (2) ◽  
pp. 118-121
Author(s):  
Shoaeb Imtiaz Alam ◽  
Md Mustafizur Rahman ◽  
Ferdoush Rayhan ◽  
ASM Farhad Ul Hasan
Keyword(s):  
Factor Viii ◽  
Good Alternative ◽  
Fresh Frozen Plasma ◽  
Haemophilia A ◽  
Soft Tissue Trauma ◽  
Fresh Frozen ◽  
Secondary Closure ◽  
Tissue Trauma ◽  
The Cost ◽  
Frozen Plasma

Haemophilia A is an X linked disorder characterized by bleeding manifestations due to deficiency of factor VIII. Administration of factor VIII is the mainstay of treatment in case of bleeding which is very costly. That’s why fresh frozen plasma is a very good alternative in the management of mild to moderate bleeding. Here we present a case of 50 years old male presented to us with traumatic scrotal haematoma who was newly diagnosed with Haemophilia A. As the patient was unable to bear the cost of factor VIII, we managed the patient by transfusing fresh frozen plasma. After raising his activity of factor VIII up to 30% which was adequate for soft tissue trauma, surgical exploration of scrotum was done. Both the testes were found viable. Evacuation of clot was done followed by secondary closure of the wound J Shaheed Suhrawardy Med Coll, December 2018, Vol.10(2); 118-121

Effect of Whole Blood Storage on Factor VIII Recovery in Fresh Frozen Plasma and Cryoprecipitate

Vox Sanguinis ◽  
1996 ◽  
Vol 71 (3) ◽  
pp. 150-154 ◽  
Author(s):  
D. P. Allersma ◽  
R. M. R. Imambaks ◽  
L. J. Meerhof
Keyword(s):  
Factor Viii ◽  
Whole Blood ◽  
Fresh Frozen Plasma ◽  
Blood Storage ◽  
Fresh Frozen ◽  
Frozen Plasma

Use of Plasma Segments for Estimating Factor VIII Activity in Pools of Fresh Frozen Plasma

Vox Sanguinis ◽  
1987 ◽  
Vol 52 (3) ◽  
pp. 254-256
Author(s):  
F.A. Ofosu ◽  
L.M. Smith ◽  
M.A. Blajchman ◽  
J. (b) Campbell ◽  
C. De Vries ◽  
...  
Keyword(s):  
Factor Viii ◽  
Fresh Frozen Plasma ◽  
Factor Viii Activity ◽  
Fresh Frozen ◽  
Frozen Plasma

scholarly journals How we choose factor VIII to treat hemophilia

Blood ◽  
2012 ◽  
Vol 119 (18) ◽  
pp. 4108-4114 ◽  
Author(s):  
Pier Mannuccio Mannucci ◽  
Maria Elisa Mancuso ◽  
Elena Santagostino
Keyword(s):  
Factor Viii ◽  
Replacement Therapy ◽  
Hemophilia A ◽  
Recombinant Dna ◽  
Tolerance Induction ◽  
Coagulation Factors ◽  
Pathogen Transmission ◽  
Recombinant Dna Technology ◽  
Mammalian Cell Cultures ◽  
Main Determinants

AbstractIn high-income countries, the large availability of coagulation factors for replacement therapy of patients with hemophilia A has raised the life expectancy of these lifelong bleeders to that of males from the general population. The practicing clinician is offered a multitude of choices among several commercial brands of factor VIII extracted from human plasma or engineered from mammalian cell cultures by means of recombinant DNA technology. This article has the goal to offer our opinions on how to choose among the different products, that we consider interchangeable relevant to their clinical efficacy in the control of bleeding and safety from pathogen transmission. Hence, the main determinants of our choices are price and the risk of occurrence of factor VIII inhibitory alloantibodies. With this as background, we present the rationale underlying the choices for different categories of patients with severe hemophilia A: previously untreated patients, multiply treated patients, and patients undergoing immune tolerance induction with large doses of factor VIII to eradicate inhibitors. Mention is also made to the possible strategies that should be implemented to make available coagulation factors for replacement therapy in developing countries.

Sign in / Sign up

Export Citation Format

Share Document